Literature DB >> 31409921

Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.

Junya Kanda1, Hiromi Hayashi2,3, Annalisa Ruggeri2,3,4, Fumihiko Kimura5, Fernanda Volt2,3, Satoshi Takahashi6, Myriam Labopin7, Shinichi Kako8, Karina Tozatto-Maio2,3,9, Shingo Yano10, Guillermo Sanz11,12, Naoyuki Uchida13, Maria Teresa Van Lint14, Seiko Kato15, Mohamad Mohty4,7, Edouard Forcade16, Heiwa Kanamori17, Jorge Sierra18, Yuju Ohno19, Riccardo Saccardi20, Takahiro Fukuda21, Tatsuo Ichinohe22, Minoko Takanashi23, Vanderson Rocha2,3, Shinichiro Okamoto24, Arnon Nagler7,25, Yoshiko Atsuta26, Eliane Gluckman2,3.   

Abstract

Large differences in patient and transplant backgrounds make it difficult to identify consistent prognostic factors of unrelated cord blood transplantation (UCBT) among different populations. Thus, we performed a collaborative study between Eurocord/ALWP-EBMT and JSHCT/JDCHCT. Adults with acute leukaemia who underwent a single UCBT were eligible. In total, 3764 and 1027 patients of the JSHCT/JDCHCT and Eurocord/ALWP-EBMT registries, respectively, were included. The median ages of the Japanese and European cohorts were 51 and 38 years, respectively. Three or more HLA mismatches were more frequently observed in the Japanese cohort. The median total nucleated cell (TNC) counts were 2.58 and 3.51 × 107/kg in the Japanese and European cohorts, respectively. Anti-thymocyte globulin was used in only 2% of the Japanese cohort compared with 65% of the European cohort. The 3-year overall survival (OS) was 41% in JSHCT/JDCHCT and 33% in Eurocord/ALWP-EBMT. In the multivariate analysis, TNC dose and HLA matching had no significant effect on OS in either cohort, whereas year of transplantation, age, and refined disease risk index affected OS in both cohorts. Despite considerable differences in characteristics between the Japanese and European cohorts, we observed similar prognostic factors affecting UCBT outcomes in adult patients with acute leukaemia in both registries.

Entities:  

Mesh:

Year:  2019        PMID: 31409921     DOI: 10.1038/s41375-019-0534-5

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  1 in total

Review 1.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

Authors:  K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

  1 in total
  6 in total

1.  Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation.

Authors:  Junya Kanda; Katsutsugu Umeda; Koji Kato; Makoto Murata; Junichi Sugita; Souichi Adachi; Katsuyoshi Koh; Maiko Noguchi; Hiroaki Goto; Nao Yoshida; Maho Sato; Yuhki Koga; Tsukasa Hori; Yuko Cho; Atsushi Ogawa; Masami Inoue; Yoshiko Hashii; Yoshiko Atsuta; Takanori Teshima
Journal:  Bone Marrow Transplant       Date:  2020-03-11       Impact factor: 5.483

2.  A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin.

Authors:  Tetsuya Nishida; Takeshi Kobayashi; Masashi Sawa; Shinichi Masuda; Yasuhiko Shibasaki; Tatsunori Goto; Noriko Fukuhara; Nobuharu Fujii; Kazuhiro Ikegame; Junichi Sugita; Takashi Ikeda; Yachiyo Kuwatsuka; Ritsuro Suzuki; Yuho Najima; Noriko Doki; Tomonori Kato; Yuichiro Inagaki; Yoshikazu Utsu; Nobuyuki Aotsuka; Masayoshi Masuko; Seitaro Terakura; Yasushi Onishi; Yoshinobu Maeda; Masaya Okada; Takanori Teshima; Makoto Murata
Journal:  Ann Hematol       Date:  2021-01-11       Impact factor: 3.673

3.  The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.

Authors:  Junya Kanda; Hiromi Hayashi; Annalisa Ruggeri; Fumihiko Kimura; Fernanda Volt; Satoshi Takahashi; Shinichi Kako; Karina Tozatto-Maio; Masamitsu Yanada; Guillermo Sanz; Naoyuki Uchida; Emanuele Angelucci; Seiko Kato; Mohamad Mohty; Edouard Forcade; Masatsugu Tanaka; Jorge Sierra; Takanori Ohta; Riccardo Saccardi; Takahiro Fukuda; Tatsuo Ichinohe; Takafumi Kimura; Vanderson Rocha; Shinichiro Okamoto; Arnon Nagler; Yoshiko Atsuta; Eliane Gluckman
Journal:  Bone Marrow Transplant       Date:  2021-10-11       Impact factor: 5.483

Review 4.  Umbilical cord blood: an undervalued and underutilized resource in allogeneic hematopoietic stem cell transplant and novel cell therapy applications.

Authors:  Patricia A Shi; Larry L Luchsinger; John M Greally; Colleen S Delaney
Journal:  Curr Opin Hematol       Date:  2022-08-29       Impact factor: 3.218

5.  Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia.

Authors:  Takaaki Konuma; Shohei Mizuno; Tadakazu Kondo; Yasuyuki Arai; Naoyuki Uchida; Satoshi Takahashi; Masatsugu Tanaka; Takuro Kuriyama; Shigesaburo Miyakoshi; Makoto Onizuka; Shuichi Ota; Yasuhiro Sugio; Yasushi Kouzai; Toshiro Kawakita; Hikaru Kobayashi; Yukiyasu Ozawa; Takafumi Kimura; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada
Journal:  Blood Cancer J       Date:  2022-05-25       Impact factor: 9.812

6.  Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012.

Authors:  Claudio G Brunstein; Paul V O'Donnell; Brent Logan; Peter Dawson; Luciano Costa; Corey Cutler; Michael Craig; William Hogan; Mary M Horowitz; Mitchell E Horwitz; Chatchada Karanes; John M Magenau; Adriana Malone; John McCarty; Joseph P McGuirk; Lawrence E Morris; Andrew R Rezvani; Rachel Salit; Sumithira Vasu; Mary Eapen; Ephraim J Fuchs
Journal:  Transplant Cell Ther       Date:  2022-04-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.